ArticleACS applied bio materials2026
Biodegradable PCL-PLGA Electrospun Nanofibers for Localized Cancer Therapy.
Article in ACS applied bio materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Localized chemotherapy offers a promising strategy to improve therapeutic efficacy while minimizing the systemic toxicity of conventional cancer treatment, particularly following tumor resection. Electrospun nanofibers are well suited for this purpose due to their high porosity, extracellular matrix-mimicking architecture, and capacity for localized drug release. In this study, electrospun nanofibers based on PCL and PLGA were developed for localized cancer therapy. Three distinct nanofibrous architectures were fabricated: PCL nanofibers, PCL-PLGA blended nanofibers, and PCL-PLGA multilayered (tetra-layered) nanofibers, and their encapsulation efficiency was determined by high-performance liquid chromatography (HPLC). Scanning electron microscopy confirmed uniform, bead-free nanofibrous morphologies, while Fourier transform infrared spectroscopy and thermal analyses verified effective polymer blending, molecular interaction, drug incorporation, and enhanced thermal stability. The incorporation of PLGA altered the degradation rate and surface wettability of the nanofibers, enabling modulation of drug release behavior. Biological evaluations demonstrated acceptable hemocompatibility, favorable interactions with RAW 264.7 macrophages, and high cytocompatibility across all formulations. Importantly, nanofiber architecture significantly influenced release profiles (curcumin dye as a model), with multilayered or blend nanofibers exhibiting reduced burst release and prolonged drug delivery compared to single-polymer systems. In addition, proliferation clonogenicity and western blotting assays confirm their corresponding high cytotoxic responses (docetaxel as a model). Overall, this work demonstrates that architectural and compositional engineering of PCL-PLGA electrospun nanofibers provides a robust and adaptable platform for localized, sustained cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.